Pharmacokinetic interaction of ketoconazole, clarithromycin, and midazolam with riociguat
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2050-6511
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Pharmacokinetic interaction of ketoconazole, clarithromycin, and midazolam with riociguat ; volume:14 ; number:1 ; day:29 ; month:8 ; year:2013 ; pages:1-4 ; date:8.2013
BMC pharmacology & toxicology ; 14, Heft 1 (29.8.2013), 1-4, 8.2013
- Urheber
-
Becker, Corina
- Beteiligte Personen und Organisationen
-
Frey, Reiner
Unger, Sigrun
Thomas, Dirk
Reber, Michael
Weimann, Gerrit
Dietrich, Hartmut
Arens, Erich R.
Mueck, Wolfgang
SpringerLink (Online service)
- DOI
-
10.1186/2050-6511-14-S1-P5
- URN
-
urn:nbn:de:1111-2016073155559
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:04 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Becker, Corina
- Frey, Reiner
- Unger, Sigrun
- Thomas, Dirk
- Reber, Michael
- Weimann, Gerrit
- Dietrich, Hartmut
- Arens, Erich R.
- Mueck, Wolfgang
- SpringerLink (Online service)
Ähnliche Objekte (12)
Pharmacokinetic Drug Interaction Studies with Enzalutamide
Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity
Clarithromycin crystalluria
Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors
Pharmacokinetic drug interaction and safety after coadministration of clarithromycin, amoxicillin, and ilaprazole: a randomised, open-label, one-way crossover, two parallel sequences study
Pharmakokinetik von Clarithromycin nach der Monotherapie mit Clarithromycin und nach der kombinierten Gabe von Clarithromycin mit Rifampicin beim Fohlen
Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults
Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models
Pharmacokinetic Drug–Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer
Effectiveness of clarithromycin in patients with yellow nail syndrome
Pharmacokinetic interaction between regorafenib and atorvastatin in rats
Midazolam Microdosing and Population Pharmacokinetic Modelling to Assess CYP3A Drug-Drug Interactions in Early Clinical Development
Pharmacokinetic Drug Interaction Studies with Enzalutamide
Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity
Clarithromycin crystalluria
Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors
Pharmacokinetic drug interaction and safety after coadministration of clarithromycin, amoxicillin, and ilaprazole: a randomised, open-label, one-way crossover, two parallel sequences study
Pharmakokinetik von Clarithromycin nach der Monotherapie mit Clarithromycin und nach der kombinierten Gabe von Clarithromycin mit Rifampicin beim Fohlen
Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults
Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models
Pharmacokinetic Drug–Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer
Effectiveness of clarithromycin in patients with yellow nail syndrome
Pharmacokinetic interaction between regorafenib and atorvastatin in rats
Midazolam Microdosing and Population Pharmacokinetic Modelling to Assess CYP3A Drug-Drug Interactions in Early Clinical Development
Pharmacokinetic Drug Interaction Studies with Enzalutamide
Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity
Clarithromycin crystalluria
Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors
Pharmacokinetic drug interaction and safety after coadministration of clarithromycin, amoxicillin, and ilaprazole: a randomised, open-label, one-way crossover, two parallel sequences study
Pharmakokinetik von Clarithromycin nach der Monotherapie mit Clarithromycin und nach der kombinierten Gabe von Clarithromycin mit Rifampicin beim Fohlen
Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults
Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models
Pharmacokinetic Drug–Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer
Effectiveness of clarithromycin in patients with yellow nail syndrome
Pharmacokinetic interaction between regorafenib and atorvastatin in rats